← Vaxart, Inc. (VXRT) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Vaxart, Inc. (VXRT)
Biological Products, (No Diagnostic Substances) · market cap $119M · as of 2026-07-13
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2027-05-15 (est.)
Phase 2
Pipeline
6
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Vaxart, Inc. (VXRT) is a ~$152M market-cap clinical-stage biotech developing oral, room-temperature-stable recombinant tablet vaccines using its proprietary VAAST platform. The company has multiple Phase 2 programs across norovirus, influenza, SARS-CoV-2, and HPV-related condyloma, with its lead norovirus asset and a VXA-CoV2-3.1 Phase 2 readout estimated around May 2027 representing the primary near-term catalyst. With $50.7M cash and an unusually long ~74-month runway, near-term dilution pressure appears limited.
The catalyst path
- 2027-05-15 (est.)Phase 2 · VXA-CoV2-3.1imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Open label Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose | Phase 2 | Norovirus Infections |
| VXA-CoV2-3.1 | Phase 2 | SARS-CoV2 |
| VXA-A1.1 | Phase 2 | Influenza |
| AP611074 5% gel | Phase 2 | Condyloma |
| VXA-G1.1-NN | Phase 2 | Norovirus Infections |
| Norovirus GI.1 Norwalk Virus Inoculum | Phase 2 | Norovirus Infections |
Price & technical context
3-month
-26.2%
6-month
-26.2%
12-month
+24.3%
52-wk range
$0.33–$0.80
vs 50-day MA
-11.0%
vs 200-day MA
-23.1%
Realized vol
87.5%
Max drawdown
-69.6%
Daily closes through 2026-09-30. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for VXRT (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 6 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.